SUFFERN, N.Y.--(BUSINESS WIRE)--Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents, bringing the total number of its issued U.S. Patents to 34.
U.S. Patent No. 8,795,959 titled “Isolated glucokinase genomic polynucleotide fragments from chromosome 7” was issued August 5, 2014. This patent continues the theme of a previously issued Ryogen patent, U.S. Patent No. 8,313,899. The new patent claims a method of detection of specified sequences from polynucleotide sequence which encodes a protein that has human glucokinase activity. Glucokinase plays an important role in the regulation of carbohydrate metabolism. It serves as a glucose sensor of the insulin-producing pancreatic cells, controls the conversion of glucose to glycogen in the liver, and regulates hepatic glucose production. Mutations in the gene for this enzyme are associated with different forms of Diabetes and Hypoglycemia.
Help employers find you! Check out all the jobs and post your resume.
